Teachers Retirement System of The State of Kentucky Acquires 8,474 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Teachers Retirement System of The State of Kentucky increased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 24.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,261 shares of the biotechnology company’s stock after purchasing an additional 8,474 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Arrowhead Pharmaceuticals were worth $2,713,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in ARWR. Tsfg LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter worth approximately $25,000. First Horizon Corp purchased a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $32,000. WPG Advisers LLC lifted its position in Arrowhead Pharmaceuticals by 384.8% during the fourth quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 431 shares during the last quarter. Hantz Financial Services Inc. boosted its stake in Arrowhead Pharmaceuticals by 177.1% in the fourth quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 471 shares in the last quarter. Finally, Elyxium Wealth LLC acquired a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $54,000. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Stock Down 3.0%

ARWR stock opened at $71.91 on Wednesday. The company has a market capitalization of $10.13 billion, a P/E ratio of -33.45 and a beta of 1.26. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $14.30 and a 12 month high of $87.83. The firm’s fifty day simple moving average is $77.86 and its 200-day simple moving average is $69.43. The company has a debt-to-equity ratio of 1.41, a current ratio of 6.23 and a quick ratio of 6.23.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.17. The firm had revenue of $73.74 million during the quarter, compared to analysts’ expectations of $73.84 million. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The firm’s revenue was down 86.4% compared to the same quarter last year. During the same quarter last year, the company posted $2.75 earnings per share. As a group, equities research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ARWR has been the topic of several analyst reports. Leerink Partners lifted their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a report on Wednesday, June 17th. Sanford C. Bernstein raised their price objective on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Royal Bank Of Canada raised their price objective on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Weiss Ratings downgraded Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Wednesday, May 20th. Finally, Morgan Stanley raised Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $78.00 to $100.00 in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $88.17.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, CFO Daniel Joseph Apel sold 13,095 shares of the stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total transaction of $934,328.25. Following the sale, the chief financial officer directly owned 162,905 shares of the company’s stock, valued at approximately $11,623,271.75. This trade represents a 7.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James C. Hamilton sold 10,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total value of $750,000.00. Following the transaction, the insider owned 226,958 shares of the company’s stock, valued at $17,021,850. The trade was a 4.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 26,065 shares of company stock valued at $1,912,662. Company insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.